Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) FCF Yield % : -799.24 (As of May. 05, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Tetraphase Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Tetraphase Pharmaceuticals's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $16.07 Mil. Therefore, Tetraphase Pharmaceuticals's FCF Yield % for today is -799.24%.

The historical rank and industry rank for Tetraphase Pharmaceuticals's FCF Yield % or its related term are showing as below:

TTPH' s FCF Yield % Range Over the Past 10 Years
Min: -799.24 Med: -88.25 Max: -42.25
Current: -799.24

During the past 10 years, the highest FCF Yield % of Tetraphase Pharmaceuticals was -42.25%. The lowest was -799.24%. And the median was -88.25%.

TTPH's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -14.39 vs TTPH: -799.24

Tetraphase Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2020 was -635.61%.

Tetraphase Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Tetraphase Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tetraphase Pharmaceuticals FCF Yield % Chart

Tetraphase Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

FCF Yield %

Get a 7-Day Free Trial

-21.13

-43.10

-30.48

-106.47

-654.84

Tetraphase Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
FCF Yield %	Get a 7-Day Free Trial															-112.29	-255.09	-442.32	-449.27	-480.22

Competitive Comparison of Tetraphase Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Tetraphase Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tetraphase Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tetraphase Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Tetraphase Pharmaceuticals's FCF Yield % falls into.

Tetraphase Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Tetraphase Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2019 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-63.778	/	9.73946
	=	-654.84%

Tetraphase Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2020 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-11.155	*	4	/	9.29152
	=	-480.22%

Tetraphase Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Tetraphase Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Tetraphase Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tetraphase Pharmaceuticals Inc (NAS:TTPH) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472

Website

http://www.tphase.com

Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.

Executives

Guy Macdonald	director	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Larry G. Edwards	director, officer: See Remarks	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
L Patrick Gage	director	C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
John Gordon Freund	director	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Geraldine Henwood	director	88 SIDNEY ST, CAMBRIDGE MA 02139
Jeffrey Chodakewitz	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Kamalam Unninayar	officer: Chief Financial Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Patrick Taylor Horn	officer: Chief Medical Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David Charles Lubner	officer: SVP and CFO	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472